Zhongsheng’s Onradivir Granules Enroll First Phase 3 Pediatric Influenza Patient
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced the enrollment and dosing of the first...
Zhongsheng Pharmaceutical
Zhongsheng Pharma’s Onradivir Granted Drug Registration in Macau
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced that its onradivir tablets have received a...
Kexing Partners with Guangdong Zhongsheng to Commercialize Onradivir Tablets in Macau
On August 5, 2025, China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced a partnership with...
Zhongsheng Pharma’s RAY1225 Enters Phase III Trial for Obesity/Overweight Treatment
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced the initiation of the multi-center, randomized,...
Guangdong Zhongsheng Wins Peking University People’s Hospital Nod for RAY1225 Phase III Trials
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received approval from...
Zhongsheng Pharma’s Anruiwei Receives NMPA Approval for Influenza A
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received marketing approval...
Zhongsheng Pharma’s Anruiwei Shows Promising Results in Pediatric Influenza A Study
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced the topline analysis data from the...
Zhongsheng Pharma’s RAY1225 Shows Positive Results in Phase II Trials for Weight Loss and Blood Glucose Reduction
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced positive top-line analysis results from dose...
Zhongsheng Pharmaceutical’s RAY1225 Gets Green Light for Phase III Study
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received approval in...
Zhongsheng Pharma Gains FDA Approval for Phase II Study of RAY1225
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received approval from...
Guangdong Zhongsheng Pharmaceutical’s RAY1225 Shows Positive Results in Phase II Study
Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a China-based pharmaceutical company, has announced positive top-line...
Guangdong Zhongsheng Pharmaceutical’s COVID-19 Drug Leritrelvir Approved in Macau
Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a pharmaceutical company based in China, has announced...
Guangdong Zhongsheng Reports Positive Phase I Results for Innovative Weight Loss Drug RAY1225
Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a China-based biopharmaceutical company, has announced promising top-line...
Zhongsheng Pharmaceutical Initiates Phase II Trials for Polypeptide Drug RAY1225 in Diabetes and Obesity
Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a Chinese pharmaceutical company, has announced the initiation...
Guangdong Zhongsheng Pharmaceutical’s ZSP1273 for Influenza A Accepted for Review by NMPA
Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a Chinese pharmaceutical company, has announced that China’s...
Guangdong Zhongsheng Launches AI Q&A Bot for Leritrelvir Drug Support
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the innovative launch of a...
ZSP1273 by Guangdong Zhongsheng Pharma Shows Promise in Phase III Flu Treatment Study
Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a China-based pharmaceutical company, has announced preliminary top-line...
Guangdong Zhongsheng Pharmaceutical Plans to Raise RMB 600 Million via Private Placement
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) is poised to raise RMB 600 million...
Guangdong Zhongsheng Pharma Initiates Phase IIb Study for ZSP1601 in NASH
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the first subject enrollment in...
Guangdong Zhongsheng’s RAY1216 Receives Conditional Approval for COVID-19 Treatment
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced that it has received conditional...